检索结果 - Matthew A. Gubens

Refine Results
  1. 1
    Long-Term Survivors of Pancreatic Cancer

    Long-Term Survivors of Pancreatic Cancer 由 Adel Kardosh, Daphne Y. Lichtensztajn, Matthew A. Gubens, Pamela L. Kunz, George A. Fisher, Christina A. Clarke

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction

    Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction 由 Paul A. Heidenreich, Matthew A. Gubens, Gregg C. Fonarow, Marvin A. Konstam, Lynne W. Stevenson, Paul G Shekelle

    出版 2004
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Long-Term Survivors of Gastric Cancer: A California Population-Based Study

    Long-Term Survivors of Gastric Cancer: A California Population-Based Study 由 Pamela L. Kunz, Matthew A. Gubens, George A. Fisher, James M. Ford, Daphne Y. Lichtensztajn, Christina A. Clarke

    出版 2012
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    ALK Testing Trends and Patterns Among Community Practices in the United States

    ALK Testing Trends and Patterns Among Community Practices in the United States 由 Peter B. Illei, William B. Wong, Ning Wu, Laura Chu, Ravindra K. Gupta, Katja Schulze, Matthew A. Gubens

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era

    Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era 由 Jonathan W. Riess, Seema Nagpal, Michael Iv, Michael Zeineh, Matthew A. Gubens, Kavitha Ramchandran, Joel W. Neal, Heather A. Wakelee

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

    Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression 由 Martina Sanlorenzo, Igor Vujic, Adil Daud, Alain P. Algazi, Matthew A. Gubens, Sara Alcántara Luna, Kevin Lin, Pietro Quaglino, Klemens Rappersberger, Susana Ortiz‐Urda

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

    A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors 由 David C. Smith, Peter D. Eisenberg, Georgy M. Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir I. Šikić

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

    Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H 由 Matthew A. Gubens, Lecia V. Sequist, James Stevenson, Steven Powell, Liza C. Villaruz, Shirish M. Gadgeel, Corey J. Langer, Amita Patnaik, Hossein Borghaei, Shadia I. Jalal, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Leena Gandhi

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC

    Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC 由 Fabrice Barlési, Edward B. Garon, Dong‐Wook Kim, Enriqueta Felip, J. Y. Han, Jin‐Hoi Kim, M-J. Ahn, Mary J. Fidler, Matthew A. Gubens, G. Castro, Veerle Surmont, Q. Li, Anne C. Deitz, Gregory M. Lubiniecki, Roy S. Herbst

    出版 2016
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study

    Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study 由 Shirish M. Gadgeel, James Stevenson, Corey J. Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza C. Villaruz, Matthew A. Gubens, Ralph J. Hauke, James Chih‐Hsin Yang, Lecia V. Sequist, Robert Bachman, Sanatan Saraf, Harry Raftopoulos, Vassiliki A. Papadimitrakopoulou

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

    Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expres... 由 Fabrice Barlési, Edward B. Garon, Dong‐Wan Kim, Enriqueta Felip, Ji‐Youn Han, Joo-Hang Kim, Myung‐Ju Ahn, Mary J. Fidler, Matthew A. Gubens, Gilberto de Castro, Veerle Surmont, Qiao Li, Anne C. Deitz, Gregory M. Lubiniecki, Roy S. Herbst

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

    Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC 由 Mark M. Awad, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, James Chih‐Hsin Yang, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Mehmet Altan, Shadia I. Jalal, Amit Panwalkar, Matthew A. Gubens, Lecia V. Sequist, Sanatan Saraf, Bin Zhao, Bilal Piperdi, Corey J. Langer

    出版 2020
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline

    Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline 由 Megan E. Daly, Navneet Singh, Nofisat Ismaila, Mara B. Antonoff, Douglas A. Arenberg, Jeffrey D. Bradley, Elizabeth A. David, Frank C. Detterbeck, Martin Früh, Matthew A. Gubens, Amy Moore, Sukhmani K. Padda, Jyoti D. Patel, Tanyanika Phillips, Angel Qin, Clifford G. Robinson, Charles B. Simone

    出版 2021
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  14. 14
    Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events

    Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events 由 Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Karmugi Balaratnam, Eduardo Cárdenas, Christina J. Falcon, Princess Margaret Lung Group, Matthew A. Gubens, Scott Huntsman, Khaleeq Khan, Min Li, Christine M. Lovly, Devalben Patel, Luna Jia Zhan, Geoffrey Liu, Melinda C. Aldrich, Adam J. Schoenfeld, Elad Ziv

    出版 2025
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

    NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer 由 Collin M. Blakely, Evangelos Pazarentzos, Victor Olivas, Saurabh Asthana, Jenny Yan, Irena Tan, Gorjan Hrustanovic, Elton Chan, Luping Lin, Dana S. Neel, W. H. Newton, Kathryn Bobb, Timothy Fouts, Jeffrey Meshulam, Matthew A. Gubens, David M. Jablons, Jeffrey R. Johnson, Sourav Bandyopadhyay, Nevan J. Krogan, Trever G. Bivona

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

    Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials 由 Roy S. Herbst, G. Lopes, D.M. Kowalski, Mizuho Nishio, Yechen Wu, Gilberto de Castro, Paul Baas, D.-W. Kim, Matthew A. Gubens, Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Mark Ayers, Andrey Loboda, Jared Lunceford, Julie Kobie, Gregory M. Lubiniecki, Maria C. Pietanza, Bilal Piperdi, Tony Mok

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC 由 Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, Jose Luis Pérez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas

    出版 2021
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

    Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study 由 Edward B. Garon, Matthew D. Hellmann, Naiyer A. Rizvi, Enric Carcereny, Natasha B. Leighl, Myung‐Ju Ahn, Joseph P. Eder, Ani Sarkis Balmanoukian, Charu Aggarwal, Leora Horn, Amita Patnaik, Matthew A. Gubens, Suresh S. Ramalingam, Enriqueta Felip, Jonathan W. Goldman, Cathie Scalzo, Erin Jensen, Debra Kush, Rina Hui

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study 由 Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi

    出版 2016
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

    24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Can... 由 Hossein Borghaei, Corey J. Langer, Shirish M. Gadgeel, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Sanatan Saraf, Steven M. Keller, Leena Gandhi

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: